SANIONA Aktie

 

Saniona has taken a step forward within its epilepsy program by initiating the scale-up and manufacturing of toxicology batches for SAN2219. This move propels the program toward clinical studies, targeted for the first half of 2026. BioStock reached out to Chief Scientific Officer, Karin Sandager Nielsen, for a comment. Read the full interview with Karin Sandager Nielsen at biostock.se: https://www.biostock.se/en/2025/03/sanionas-cso-we-are-on-track-with-san2219/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/...

Saniona has secured guarantee commitments for its ongoing TO4 warrant exercise, running from March 18 to April 1, which could raise up to SEK 115 million. The board and CEO Thomas Feldthus have also pledged full participation, signaling strong confidence in the company's future direction. We reached out to Feldthus for insight into why he and the board are committing fully to the initiative. Read the full interview with Thomas Feldthus at biostock.se: https://www.biostock.se/en/2025/03/sanionas-ceo-the-to4-proceeds-give-us-flexibility-to-secure-the-best-deals/ This is a press release...

Saniona has appointed Pierandrea Muglia, M.D., as Chief Medical Officer, bringing over three decades of expertise from large international pharmaceutical companies, biotech and neuroscience research. A board member since 2023, Muglia has seen Saniona's pipeline grow and its partnerships, like the $610 million deal with Acadia Pharmaceuticals, thrive. Now, he'll steer the company's clinical and regulatory efforts as it prepares three candidates for phase II trials. We talked with Muglia to explore his visions. Read the full interview at biostock.se: https://www.biostock.se/en/2025/03/...

Saniona is advancing its treatments for epilepsy and neurological disorders, with SAN2355 – a selective epilepsy therapy – now in GMP-manufacturing and toxicology studies, aiming for a clinical trial application by late 2025. Meanwhile, Saniona and Acadia Pharmaceuticals has completed two phase I MAD cohorts for ACP-711, formerly SAN711, confirming its safety in healthy volunteers. In addition, from March 18 to April 1, 2025, Saniona's TO4 warrant program could raise up to SEK 188.4 million. We spoke with CEO Thomas Feldthus to learn more. Read the full interview with Thomas Feldthus at...

Saniona's key milestone in 2024 was securing an exclusive worldwide licensing agreement with Acadia Pharmaceuticals worth up to USD 610 million. This deal not only drives the continued development of SAN711 as a promising treatment for neurological disorders, but also accelerates the progression of multiple drug candidates in Saniona's pipeline. – As we close 2024 and look ahead to 2025, I am pleased to share the significant progress Saniona has made in advancing our pipeline, strengthening our financial position, and setting the stage for multiple strategic opportunities, says Thomas...

Saniona has announced that Cephagenix, a joint venture with Professor Jes Olesen at the University of Copenhagen, has successfully raised up to 9 MEUR  in tranched seed financing. The funding round was led by AdBio Partners and AbbVie Ventures and aims to accelerate the development of Cephagenix's vascular KATP channel inhibitor program, targeting novel anti-migraine therapies. BioStock reached out to Saniona's CEO Thomas Feldthus for a comment. Read the interview with Thomas Feldthus at biostock.se: https://www.biostock.se/en/2025/01/saniona-backed-cephagenix-secures-9-meur-in-seed-...

Saniona has announced a partnership with Acadia Pharmaceuticals to develop and commercialize SAN711. The total potential deal size is USD 610 million, including an upfront payment of USD 28 million—almost mirroring Saniona's market value before the announcement. BioStock reached out to CEO Thomas Feldthus for a comment. Read the full interview with Thomas Feldthus at biostock.se: https://www.biostock.se/en/2024/11/sanionas-ceo-the-deal-with-acadia-is-significant/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/...

Acadia signs a $610 million exclusive global license agreement with Saniona to develop and commercialize SAN711 for neurological disorder indications....

BRIEF-Acadia Pharmaceuticals Announces Exclusive License Agreement With Saniona For SAN711 Nov 26 (Reuters) - ACADIA Pharmaceuticals Inc ACAD.O : ACADIA PHARMACEUTICALS ANNOUNCES EXCLUSIVE LICENSE AGREEMENT WITH SANIONA FOR SAN711 ACADIA PHARMACEUTICALS INC - TO INITIATE PHASE 2 STUDY OF SAN711 IN 2026 ACADIA PHARMACEUTICALS INC - SANIONA TO RECEIV...

Last week, Saniona announced that its partner Medix in Mexico had not received regulatory approval for tesofensine. In a new update, Saniona clarifies that Medix, as the primary applicant and manager of the approval process in Mexico, is actively engaging with the regulatory agency to resolve the matter. Read the article at biostock.se: https://www.biostock.se/en/2024/11/saniona-provided-a-tesofensine-update/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/...

Saniona's collaboration with Boehringer Ingelheim has advanced to the lead optimization stage, triggering a 500,000 Euro research milestone payment to Saniona. The partnership aims to address the cognitive impairments associated with schizophrenia, a critical aspect of the disorder that profoundly affects patients' daily lives. Read the article at biostock.se: https://www.biostock.se/en/2024/10/saniona-achieves-milestone-with-boehringer-ingelheim/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/...

Saniona has initiated dosing of the first subjects with SAN711 in a phase I multiple ascending dose biomarker study, aiming to release topline data by the end of the year. The CEO, Thomas Feldthus, see this as a milestone and a crucial step towards the goal of starting a clinical proof-of-concept study in children with absence seizures next year. – This study with SAN711 in healthy volunteers offers valuable insights into the appropriate dosing for our phase II trial, helping to ensure positive outcomes. Read the full article at biostock.se: https://www.biostock.se/en/2024/10/saniona-has-...

Saniona has announced significant progress in the preclinical development of the epilepsy drug candidate SAN2355 to treat focal-onset seizures. BioStock talked to CEO Thomas Feldthus to learn more. Read the full interview with Thomas Feldthus at biostock.se: https://www.biostock.se/en/2024/10/sanionas-ceo-san2355-is-a-highly-promising-candidate-for-commercialization/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/...

Saniona has received approval to initiate a phase I multiple ascending dose and biomarker study in adults for SAN711, marking a key milestone toward a clinical proof-of-concept trial in children with absence seizures, planned for 2025. – We are confident in its safety and believe it holds potential not only for this condition but for other epilepsy indications, and possibly beyond epilepsy, says CEO Thomas Feldthus. Read the full interview with Thomas Feldthus at biostock.se: https://www.biostock.se/en/2024/09/saniona-comments-on-the-approval-to-initiate-epilepsy-study/ This is a...

In its recently published interim report, Saniona's CEO Thomas Feldthus highlights the external interest in one of the clinical candidates and two of the preclinical candidates, while reiterating the target of delivering clinical updates for SAN711 and SAN2355 before year-end. The company is also eyeing a possible first market approval of tesofensine, targeting the obesity market. – We are awaiting the final decision for approval of tesofensine for obesity in Mexico. If successful, Saniona will be entitled to an upfront payment and double-digit royalties on product sales. Read the article...

Saniona is currently advancing its epilepsy assets to provide clinical proof-of-concept for SAN711 and preparing SAN2355 for phase I. Meanwhile, the company is anticipating the approval of tesofensine in Mexico this year, while scouting for yet more partnerships. BioStock spoke with the company's CEO to learn more. – We see interest in several of our assets and have several exciting leads to pursue. We have weekly meetings with potential partners and open data rooms for new companies every month. I'm confident that we will succeed, says Thomas Feldthus. Read the full interview with Thomas...